182 related articles for article (PubMed ID: 26919451)
21. Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study.
Maura G; Blotière PO; Bouillon K; Billionnet C; Ricordeau P; Alla F; Zureik M
Circulation; 2015 Sep; 132(13):1252-60. PubMed ID: 26199338
[TBL] [Abstract][Full Text] [Related]
22. Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity.
Siegal DM; Curnutte JT; Connolly SJ; Lu G; Conley PB; Wiens BL; Mathur VS; Castillo J; Bronson MD; Leeds JM; Mar FA; Gold A; Crowther MA
N Engl J Med; 2015 Dec; 373(25):2413-24. PubMed ID: 26559317
[TBL] [Abstract][Full Text] [Related]
23. Retrospective Evaluation of Postoperative Bleeding Events in Patients Receiving Rivaroxaban After Undergoing Total Hip and Total Knee Arthroplasty: Comparison with Clinical Trial Data.
Wood RC; Stewart DW; Slusher L; El-Bazouni H; Cluck D; Freshour J; Odle B
Pharmacotherapy; 2015 Jul; 35(7):663-9. PubMed ID: 26095331
[TBL] [Abstract][Full Text] [Related]
24. [Acute Carpal Tunnel Syndrome due to Spontaneous Bleeding after Taking Rivaroxaban (Xarelto®)].
Hohendorff B; Biber F; Sauer H; Franke J
Handchir Mikrochir Plast Chir; 2016 Jun; 48(3):168-70. PubMed ID: 25970598
[TBL] [Abstract][Full Text] [Related]
25. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.
Beyer-Westendorf J; Ehlken B; Evers T
Europace; 2016 Aug; 18(8):1150-7. PubMed ID: 26830891
[TBL] [Abstract][Full Text] [Related]
26. Spontaneous, Life-Threatening Hemorrhagic Cardiac Tamponade Secondary to Rivaroxaban.
Kham NM; Song M
Am J Ther; 2016; 23(4):e1128-31. PubMed ID: 26035030
[TBL] [Abstract][Full Text] [Related]
27. Direct oral anticoagulant drugs (DOAC).
Blum RA; Lindfield D
J Cataract Refract Surg; 2016 Jan; 42(1):171-2. PubMed ID: 26948793
[No Abstract] [Full Text] [Related]
28. Association of rivaroxaban anticoagulation and spontaneous vitreous hemorrhage.
Jun JH; Hwang JC
JAMA Ophthalmol; 2015 Oct; 133(10):1184-6. PubMed ID: 26111247
[TBL] [Abstract][Full Text] [Related]
29. Superior mesenteric artery thrombosis after abrupt discontinuation of rivaroxaban.
Adams CB; Acquisto NM; Rotoli JM; LoStracco T; Shamaskin AR; Pasternack JS
Am J Emerg Med; 2016 Apr; 34(4):764.e5-7. PubMed ID: 26439093
[TBL] [Abstract][Full Text] [Related]
30. A rare cause of GI bleeding in a patient with cutaneous vascular malformations.
Tsoutsouki J; Laskaratos FM; Mason S; Smith M; Sinha L
Gut; 2016 Nov; 65(11):1792. PubMed ID: 26809732
[No Abstract] [Full Text] [Related]
31. Dosing of rivaroxaban by indication: getting the right dose for the patient.
Escolar G; Carne X; Arellano-Rodrigo E
Expert Opin Drug Metab Toxicol; 2015; 11(10):1665-77. PubMed ID: 26329812
[TBL] [Abstract][Full Text] [Related]
32. Impact of gender on safety and efficacy of Rivaroxaban in adolescents & young adults with venous thromboembolism.
Krause M; Henningsen A; Torge A; Juhl D; Junker R; Kenet G; Kowalski D; Limperger V; Mesters R; Anonymous ; Rocke A; Shneyder M; Clausnizer H; Schiesewitz H; Nowak-Göttl U
Thromb Res; 2016 Dec; 148():145-151. PubMed ID: 27687905
[No Abstract] [Full Text] [Related]
33. Which oral anticoagulant for atrial fibrillation.
Med Lett Drugs Ther; 2016 Apr; 58(1492):45-6. PubMed ID: 27049507
[No Abstract] [Full Text] [Related]
34. Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials.
Beyer-Westendorf J; Lensing AW; Arya R; Bounameaux H; Cohen AT; Wells PS; Middeldorp S; Verhamme P; Hughes R; Kucher N; Pap AF; Trajanovic M; Prins MH; Prandoni P; Weitz JI
Thromb Res; 2017 Jan; 149():29-37. PubMed ID: 27886530
[TBL] [Abstract][Full Text] [Related]
35. Delayed-onset heparin-induced thrombocytopenia without thrombosis in a patient receiving postoperative thromboprophylaxis with rivaroxaban.
Tardy-Poncet B; Piot M; Montmartin A; Burdier A; Chalayer E; Tardy B
Thromb Haemost; 2015 Aug; 114(3):652-4. PubMed ID: 26062524
[No Abstract] [Full Text] [Related]
36. Adrenal hemorrhage in patients with primary antiphospholipid syndrome: imaging findings.
Provenzale JM; Ortel TL; Nelson RC
AJR Am J Roentgenol; 1995 Aug; 165(2):361-4. PubMed ID: 7618557
[TBL] [Abstract][Full Text] [Related]
37. Greenlight™ photovaporization of the prostate in patients under rivaroxaban: Lesson learned after the first cases.
Charbonneau H; Pathak A; Albenque JP; Misrai V
Prog Urol; 2016 Apr; 26(5):273-5. PubMed ID: 26970929
[No Abstract] [Full Text] [Related]
38. Prophylactic subcutaneous heparin therapy as a cause of bilateral adrenal hemorrhage.
Hardwicke MB; Kisly A
Arch Intern Med; 1992 Apr; 152(4):845-7. PubMed ID: 1558445
[TBL] [Abstract][Full Text] [Related]
39. Fatal intracerebral bleeding under rivaroxaban.
Stöllberger C; Bastovansky A; Finsterer J
Int J Cardiol; 2015 Dec; 201():110-2. PubMed ID: 26296048
[TBL] [Abstract][Full Text] [Related]
40. The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study.
Haas S; Holberg G; Kreutz R; Lassen MR; Mantovani L; Haupt V; Vogtländer K; Turpie AG
Vasc Health Risk Manag; 2016; 12():209-18. PubMed ID: 27274266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
